Evidence map›Paper›PMID 33596218›Full record

ArticlePloS one2021

Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro.

Martina Morokutti-Kurz, Maria Fröba, Philipp Graf, Maximilian Große, Andreas Grassauer, Janina Auth, Ulrich Schubert, Eva Prieschl-Grassauer

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
23.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Carrageenan fromBiosensors · 2023
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Martina Morokutti-KurzMarinomed Biotech AG, Korneuburg, Austria.
Maria FröbaInstitute of Virology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Philipp GrafMarinomed Biotech AG, Korneuburg, Austria.
Maximilian GroßeInstitute of Virology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Andreas GrassauerMarinomed Biotech AG, Korneuburg, Austria.
Janina AuthInstitute of Virology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Ulrich SchubertInstitute of Virology, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Eva Prieschl-GrassauerMarinomed Biotech AG, Korneuburg, Austria.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEMarinomed Biotech (Austria) · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the absence of a vaccine and other effective prophylactic or therapeutic countermeasures the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) remains a significant public health threat. Attachment and entry of coronaviruses including SARS-CoV-2 is mainly mediated by the spike glycoprotein. Here, we show that iota-carrageenan can inhibit the cell entry of the SARS-CoV-2 spike pseudotyped lentivirus in a dose dependent manner. SARS-CoV-2 spike pseudotyped lentivirus particles were efficiently neutralized with an IC50 value of 2.6 μg/ml iota-carrageenan. Experiments with patient isolated wild type SARS-CoV-2 virus showed an inhibition of replication in a similar range. In vitro data on iota-carrageenan against various Rhino- and endemic Coronaviruses showed similar IC50 values and translated readily into clinical effectiveness when a nasal spray containing iota-carrageenan demonstrated a reduction of severity and duration of symptoms of common cold caused by various respiratory viruses. Accordingly, our in vitro data on SARS-CoV-2 spike pseudotyped lentivirus and replication competent SARS-CoV-2 suggest that administration of iota-carrageenan may be an effective and safe prophylaxis or treatment for SARS-CoV-2 infections.

Indexed as

AnimalsAntibodies, ViralAntiviral AgentsCarrageenanChlorocebus aethiopsCOVID-19COVID-19 Drug TreatmentHEK293 CellsHumansLentivirusMiddle AgedSARS-CoV-2Spike Glycoprotein, CoronavirusVero CellsVirus InternalizationVirus ReplicationAntibodies, ViralAntiviral AgentsCarrageenanSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID33596218
PMCPMC7888609
OpenAlexW3132612827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.